Stage IV Lung Cancer: Joanne's Patient Story

Patient Info: Joanne Sabol, Female, 60s | Stage IV

Metastatic Site: abdomen

More than 2 years after starting pembrolizumab for recurrent Stage IV lung cancer, Joanne had an 81% tumor reduction and continued to feel well while remaining on treatment.

Memorial Sloan KetteringRead more →

Stage IV Lung Cancer: Michael's Patient Story

Patient Info: Michael O’Donnell, Male | Stage IV

More than 5 years after a Stage IV diagnosis, Michael remained on immunotherapy with disease controlled to his and his doctor’s satisfaction and scans every 3 months to watch for growth.

Small Cell Lung Cancer: Nina's Patient Story

Patient Info: Nina, Female

Nina’s tumors began shrinking within weeks of starting trial immunotherapy, and she remained on the trial for 3 years without treatment side effects.

Stage IV Lung Cancer: Mary's Patient Story

Patient Info: Mary Lynn Moser, Female | Stage IV

Metastatic Site: brain

Mary Lynn wrote this message before her death after nearly 10 years with lung cancer and more than 5 years with brain metastases, while receiving aggressive immunotherapy and chemotherapy.

Stage III KRAS Lung Cancer: Bill's Survivor Story

Patient Info: Bill Morris, Male | Stage III

Biomarkers: KRAS

After multimodal treatment, Bill had remained actively cancer-free for more than 3 years and used his experience to support other patients.

Aggressive lung cancer with bone metastases and concurrent localized breast cancer

Patient Info: Anonymized, Female | Stage IV

Metastatic Site: Bone: skull, spine, clavicle

The patient was still receiving carboplatin and Taxol for aggressive lung cancer with bone metastases, while her caregiver reported rapid clinical improvement, pain relief, disappearance of a visible forehead metastasis, and 1 cm reduction in a concurrent localized breast tumor.

Lung Cancer: Sandra's Patient Story

Patient Info: Sandra, Female, 40s

Sandra was receiving immunotherapy for lung cancer and described the tumor as responding well and decreasing in size.

Stage IV Small Cell Lung Cancer: Sylvane's Patient Story

Patient Info: Sylvane, Female, 70+ | Stage IV

Metastatic Site: Bone; adrenal glands

After 3 chemotherapy cycles for Stage IV SCLC, Sylvane’s lung tumor had shrunk by half and bone and adrenal metastases had completely regressed, with a final chemo-immunotherapy cycle and then immunotherapy planned.

Stage IV Non-Small Cell Lung Cancer: Usha's Patient Story

Patient Info: Usha Jain, Female | Stage IV

Biomarkers: Tumor genetic profile available for navigation review, but specific results are not reported

Stage IV NSCLC after nearly 2 years of chemotherapy and immunotherapy, followed by watchful monitoring with routine scans; clinical trials were reviewed but not pursued.

GO2 FoundationRead more →

Stage IV Non-Small Cell Lung Cancer: Amy's Patient Story

Patient Info: Amy, Female | Stage IV

Metastatic Site: Neck lymph node; bones — hips, femurs, foot; adrenal…

Living 5 years after Stage IV squamous NSCLC diagnosis, after Keytruda did not work and treatment included bone radiation, SBRT to the lung nodule, and adrenal cryoablation.

Lung Cancer Research FoundationRead more →

Stage IV EGFR Non-Small Cell Lung Cancer: Rhonda's Patient Story

Patient Info: Rhonda Martin, Female | Stage IV

Biomarkers: EGFR-positive mutation

Metastatic Site: Brain; spine; hip bone; lymph nodes; cerebrospinal…

Rhonda Martin passed away on January 9, 2023 from complications of Stage IV EGFR-positive lung cancer, nearly 5 years after diagnosis in March 2018.

Lung Cancer Research FoundationRead more →

Stage III Lung Adenocarcinoma: Becky's Survivor Story

Patient Info: Becky Manning, Female, 40s | Stage III

After surgery, chemotherapy and 8 months of nivolumab on a clinical trial, Becky was no longer on active treatment, had no evidence of disease, felt well, and returned to MSK every 6 months for follow-up.

Memorial Sloan KetteringRead more →

Delayed adrenal insufficiency after lung cancer immunotherapy

Patient Info: Anonymized, male, 60s | Stage II

Imaging and bronchoscopy in November 2024 showed no lung-cancer recurrence or metastasis. By June 2026, he had not experienced another adrenal crisis while continuing hormone replacement.

PubMed CentralRead more →

A man with lung cancer develops kidney and lung side effects during durvalumab treatment

Patient Info: Anonymized, Male, 60s

Alive at 200 weeks with sustained improvement in proteinuria and kidney injury after durvalumab was discontinued.

PubMed CentralRead more →

Stage IV Lung Adenocarcinoma Discovered After Cancer Cells Were Found in a Stroke Clot

Patient Info: Anonymized, male, 70+ | Stage IV

Biomarkers: PD-L1 high; no actionable driver alteration

Metastatic Site: brain

New frontal brain metastases developed during treatment, and he died 51 days after the stroke that led to discovery of his lung cancer.

PubMed CentralRead more →

Severe blood-clotting disorder, liver injury, and reversible kidney injury during treatment for Stage IV lung cancer

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: PD-L1 about 1%; KRAS mutation

Metastatic Site: bone (right 4th and 5th ribs)

Restaging before cycle 4 showed a partial response. Cancer treatment was then interrupted as severe acquired iTTP, cholestatic liver injury, and reversible acute kidney injury required intensive management.

PubMed CentralRead more →

Stage IIIB lung cancer: heart inflammation from durvalumab immunotherapy, mistaken at first for tumor spreading to the heart

Patient Info: Anonymized, Female, 70+ | Stage III

Biomarkers: No actionable driver mutations identified; PD-L1 tumor proportion score <1%

She recovered cardiac function after treatment for durvalumab-associated myocarditis and remained without lung-cancer relapse or cardiac decline for more than 4 years, with no additional anticancer therapy.

PubMed CentralRead more →

Long-term lung cancer control after immunotherapy-related diabetes

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: PD-L1 80%; EGFR, ALK, ROS1 and BRAF negative

Metastatic Site: brain|liver

After years of disease control off pembrolizumab, a new brain lesion appeared in December 2025 and was treated with focused radiation. He remained clinically stable under oncology follow-up.

PubMed CentralRead more →

Long-term lung cancer response complicated by immune-related lung inflammation

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: KRAS mutation; PD-L1 90%

Metastatic Site: pleura|lungs|peritoneum|bone|brain

By October 2025, the lung inflammation had resolved and she remained in systemic and intracranial remission.

PubMed CentralRead more →

Complete response to pembrolizumab despite treatment-related lung inflammation

Patient Info: Anonymized, Male, 40s | Stage IV

Biomarkers: PD-L1 70%

Metastatic Site: pleura|bone

By November 2025, serial imaging continued to show a complete response without disease progression.

PubMed CentralRead more →

Stable lung cancer after recovery from a severe immunotherapy complication

Patient Info: Anonymized, Male, 60s

At 8-month follow-up, the primary lung tumor remained radiologically stable on maintenance chemotherapy without evidence of progression.

PubMed CentralRead more →

Stage IVA EGFR-mutant lung adenocarcinoma: clonal evolution, chemoimmunotherapy response, osimertinib rechallenge, and death after progression

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: Markers changed over time: started with EGFR L747S/L858R; later MET-amplified, PD-L1 TPS 80%, high TMB clone; later EGFR reappeared.

Metastatic Site: pleura, peritoneal nodule, retroperitoneal lymph nodes

The patient died on 30 April 2025 after progression through multiple lines and infection related to treatment-associated myelosuppression.

PubMed CentralRead more →

Extensive-stage small cell lung cancer: multi-line treatment complicated by glucocorticoid-refractory immune-related cystitis

Patient Info: Anonymized, Male, 50s

Biomarkers: No molecular biomarkers reported for SCLC. Bladder biopsy during cystitis showed mostly CD3/CD8-positive T-cell inflammation.

As of December 2025, the cancer had progressed through multiple systemic lines, new brain metastasis had appeared, and care had shifted to palliative symptomatic treatment; immune-related cystitis had resolved after prednisone plus mycophenolate mofetil.

PubMed CentralRead more →

Stage IV PD-L1-high lung adenocarcinoma: remission on chemotherapy after tislelizumab-associated KLHL11-IgG cerebellitis

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: PD-L1-high lung adenocarcinoma with EGFR/ALK/ROS1 wild type and TTF-1 positive. KLHL11-IgG was linked to cerebellitis.

Metastatic Site: M1a disease; specific metastatic site not otherwise…

At 1-year neurologic follow-up, the cerebellitis had markedly improved, serum KLHL11-IgG was negative, brain MRI lesions had resolved, and lung adenocarcinoma remained in remission on cisplatin plus pemetrexed.

PubMed CentralRead more →